Preprint Watch 2026-05-24: 1 Clinical Failures Flagged for TNF | Claidex

Q: Why was this TNF preprint flagged?

1 prior Claidex failure claim matched the target-disease mechanism. This bioRxiv preprint reports on TNF biology in a setting adjacent to 1 indexed Claidex claim(s). The dominant mechanism described in the abstract is signaling pathway architecture, which does not directly replicate or contradict the failure modes documented in the matching post-mortems (inb03-soluble-tnf-covid19-ards-futility). The closest contact with the failure record is that any new TNF-directed program should explicitly address the prior efficacy or strategic failures cataloged in those posts before opening a new Phase 2 design.

Claidex Preprint Watch

doi:10.64898/2026.01.07.698212

Preprint WatchModerateMay 24th, 2026

Lapatinib Suppressed the Expression of Proinflammatory Cytokines and Alleviated Pain Behavior in a Mouse Model of Postoperative Pain

Kyomuhangi, A.

Lapatinib Suppressed the Expression of Proinflammatory Cytokines and Alleviated Pain Behavior in a Mouse Model of Postoperative Pain

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

This bioRxiv preprint reports on TNF biology in a setting adjacent to 1 indexed Claidex claim(s). The dominant mechanism described in the abstract is signaling pathway architecture, which does not directly replicate or contradict the failure modes documented in the matching post-mortems (inb03-soluble-tnf-covid19-ards-futility). The closest contact with the failure record is that any new TNF-directed program should explicitly address the prior efficacy or strategic failures cataloged in those posts before opening a new Phase 2 design.

Abstract excerpt

Postoperative pain remains a major clinical challenge, as inadequate management can delay functional recovery, prolong hospitalization, and increase the risk of chronic pain development. Opioid analgesics, while considered the gold standard for treating severe acute postoperative pain, are limited by adverse effects such as respiratory depression, dependence, and opioid-induced hyperalgesia, the latter being a key driver of persistent postoperative pain. Lapatinib, originally developed as an anticancer therapy, has recently shown analgesic potential in both preclinical and clinical studies. Importantly, unlike opioids, lapatinib does not appear to activate central reward pathways, thereby minimizing the risk of dependence. Although its efficacy has been investigated in several chronic pain models, its role in acute postoperative pain and the associated inflammatory response has not been explored. In this study, we demonstrated that lapatinib exerts anti-inflammatory effects in vitro by suppressing proinflammatory mediators (TNF, IL-1{beta}, IL-6, COX-2, MMP, chemokines, mPGES-1 and PGE2) in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. In a mouse model of postoperative pain, preoperative administration of lapatinib attenuated both mechanical allodynia and thermal hyperalgesia. These behavioral effects were accompanied by decreased proinflammatory mediator expression (TNF, IL-1{beta}, IL-6, COX-2, and mPGES-1) and increased IL-10 levels in the injured paw tissue. Our findings highlight lapatinib as a promising candidate for repurposing as a novel analgesic for postoperative pain. Its targeted mechanism of action and lower potential for adverse effects compared with opioids support further investigation into its clinical utility in pain management.

Matching Claidex post-mortems

1 of 1 indexed

May 20, 2026INB03 in COVID-19 ARDS: Why a Selective Soluble TNF Strategy Did Not Separate From PlaceboINB03 (XPro1595, pegipanermin)EfficacyMRS 43

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.